Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions
Top Cited Papers
- 30 May 2000
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 101 (21) , 2510-2517
- https://doi.org/10.1161/01.cir.101.21.2510
Abstract
Background—Human serum paraoxonase (PON1) exists in two polymorphic forms: one that differs in the amino acid at position 192 (glutamine and arginine, Q and R, respectively) and the second one that differs in the amino acid at position 55 (methionine and leucine, M and L, respectively). PON1 protects LDL from oxidation, and during LDL oxidation, PON1 is inactivated. Methods and Results—The present study compared PON1 isoforms Q and R for their effect on lipid peroxide content in human coronary and carotid lesions. After 24 hours of incubation with PON1Q or PON1R (10 arylesterase units/mL), lipid peroxides content in both coronary and carotid lesion homogenates (0.1 g/mL) was reduced up to 27% and 16%, respectively. The above incubation was associated with inactivation of PON1Q and PON1R by 15% and 45%, respectively. Lesion cholesteryl linoleate hydroperoxides and cholesteryl linoleate hydroxides were hydrolyzed by PON1 to yield linoleic acid hydroperoxides and linoleic acid hydroxides. Furthermore, lesion and pure linoleic acid hydroperoxides were reduced to yield linoleic acid hydroxides. These results thus indicate that PON1 demonstrates esterase-like and peroxidase-like activities. Recombinant PON1 mutants in which the PON1-free sulfhydryl group at cysteine-284 was replaced with either alanine or serine were no longer able to reduce lipid peroxide content in carotid lesions. Conclusions—We conclude that PON1 may be antiatherogenic because it hydrolyzes lipid peroxides in human atherosclerotic lesions.Keywords
This publication has 26 references indexed in Scilit:
- Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase ActivitiesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.Journal of Clinical Investigation, 1998
- Oxidation of High Density LipoproteinsPublished by Elsevier ,1998
- Regulation of Body Adiposity and the Problem of ObesityArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Lesioned Low-Density Lipoprotein in Atherosclerotic Apolipoprotein E-Deficient Transgenic Mice and in Humans Is Oxidized and AggregatedBiochemical and Biophysical Research Communications, 1995
- Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonaseAtherosclerosis, 1993
- Identification of a distinct human high‐density lipoprotein subspecies defined by a lipoprotein‐associated protein, K‐45European Journal of Biochemistry, 1993
- The molecular basis of the human serum paraoxonase activity polymorphismNature Genetics, 1993
- Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitusAtherosclerosis, 1991
- Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.Journal of Clinical Investigation, 1989